RNA-based therapeutics in cardiovascular disease

Tan Phát Pham, Veerle Kremer, Reinier A. Boon*

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review


Purpose of reviewCardiovascular disease is the leading cause of death globally, with the number of deaths rising every year. Much effort has gone into development of new treatment strategies. Many RNA species have important regulatory functions in disease initiation and progression, providing interesting new treatment options. This review focuses on different classes of RNA-based therapeutics and provides examples of current clinical and preclinical studies. Current challenges that prevent clinical translation and possibilities to overcome them will be discussed.Recent findingsDifferent RNA-based molecules have been developed, such as antisense oligos, microRNA mimics and small interfering RNAs. Modifications are used to prevent degradation and immune activation and improve affinity. Additionally, in order to improve delivery of the RNA molecules to the target tissues, viral or nonviral vectors can be used.SummaryRNA-based therapy has been shown to be a promising new treatment strategy for different disorders. However, several challenges, such as delivery problems and low efficacy remain. Future research will likely focus on effective delivery to target tissues in order to improve efficacy and avoid harmful side-effects.
Original languageEnglish
Pages (from-to)191-198
Number of pages8
JournalCurrent opinion in cardiology
Issue number3
Early online date14 Feb 2020
Publication statusPublished - 2020

Cite this